WatersWAT +0.82%94 Buyback Yield % is 0.03 as of Jul. 02, 2026, which is 99% below its 10-year median of 2.55. GuruFocus rates WAT with a GF Score™ of 94/100 and a GF Value™ of $420.51 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 89 Medical Diagnostics & Research companies, Waters ranks better than 64.04% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Waters's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Waters's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Waters Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Waters's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Waters's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Waters (WAT) has a Buyback Yield % of 0.03 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Waters and its competitors. This is 99% below median its historical median of 2.55. Over the past decade, Waters' Buyback Yield % has ranged from 0.03 to 16.97. According to the industry distribution chart, Waters ranks #32 out of 89 companies in the Medical Diagnostics & Research industry, placing it in the top 36%.
Is Waters' Buyback Yield % too high?
Waters' current Buyback Yield % of 0.03 is 99% below median its 10-year median of 2.55. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 16.97. Based on the distribution chart, Waters ranks #32 out of 89 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Waters has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Waters' Buyback Yield % compare to NTRA and A?
According to the Medical Diagnostics & Research industry distribution chart, Waters ranks #32 out of 89 companies for Buyback Yield %. This puts Waters in the upper half of its industry. Historically, Waters' own Buyback Yield % has ranged from 0.03 to 16.97 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Waters and its competitors. Waters's current Buyback Yield % is 0.03, which is 99% below median its own 10-year median of 2.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Waters stock overvalued right now?
Based on GuruFocus' analysis, Waters (WAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $420.51, compared to a current price of $378.13 — trading 10.1% below its estimated fair value. The current Buyback Yield % is 0.03, which is 99% below median its 10-year median of 2.55. Waters' overall GF Score™ is 94/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Waters (WAT), the current Buyback Yield % is 0.03 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Waters (WAT) Overvalued in 2026?
Based on GuruFocus' analysis, Waters stock appears to be undervalued.
The current stock price of $378.13 is trading 10.1% below its estimated GF Value™ of $420.51.
GuruFocus considers Waters to be Modestly Undervalued.
Key valuation signals for WAT:
Buyback Yield %: 0.03 (99% below median its 10-year median of 2.55)
GF Value™: $420.51 vs. price of $378.13 (10.1% below fair value)
No single metric tells the full story. See the WAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.
94GF Score
Get the complete analysis for WAT
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAT has been successfully added to your 
